ARTICLE BY LOUIS

  • Include CDMOs In “Drugs, Money And Secret Handshakes”
    Include CDMOs In “Drugs, Money And Secret Handshakes”

    “Drugs, Money, and Secret Handshakes” is one hundred power-packed pages from author Robin Feldman, the Arthur J. Goldberg Distinguished Professor of Law at the University of California Hastings. Feldman provided Outsourced Pharma  a pre-publication copy of the book. Here’s part one of my review.

  • A Biotech's Guide To Selecting CDMOs: “35 Or 6 To 2”
    A Biotech's Guide To Selecting CDMOs: “35 Or 6 To 2”

    How one biotech started with a list of 35 possible CDMOs and whittled that list down to two.

  • I Outsource, Therefore I Exist
    I Outsource, Therefore I Exist

    Today, the success of your programs has never been more contingent upon selecting and working effectively with your service partners. This is what our annual CMO Leadership Awards are all about.

  • How Smaller Sponsors Can Compete For Attention At CDMOs
    How Smaller Sponsors Can Compete For Attention At CDMOs

    Outsourced Pharma brought together a panel of experts at sponsor companies to discuss specifically how small biopharma can compete for attention at CDMOs.

  • Sponsors And Providers Reaching Financial Summits
    Sponsors And Providers Reaching Financial Summits

    Tim Scott, founder and CEO at both a CDMO and start-up biotech, maps out financial understanding for leaders of both approaches.

  • BeiGene Exec Talks Candidly About Quality, Compliance, And Outsourcing
    BeiGene Exec Talks Candidly About Quality, Compliance, And Outsourcing

    Outsourced Pharma Chief Editor Louis Garguilo continues his coverage of the current state of China pharma manufacturing by interviewing Diana Francis, VP of quality and compliance for BeiGene.

  • Biopharma Supply Chains At Industry 4.0
    Biopharma Supply Chains At Industry 4.0

    To get to a full digital dialogue that includes everything from AI to blockchain to machine learning, drug sponsors and CDMOs alike will need to muster their resources to usher in what the rest of the world already calls Industry 4.0.

  • 7 Reasons There Was Never Going To Be A Bioprocessing Capacity Crunch
    7 Reasons There Was Never Going To Be A Bioprocessing Capacity Crunch

    “Basically, industry perceives, reports, and expects no major capacity crunches” related to global bioprocessing needs. So concludes an editor of BioPlan Associates, Inc.’s Fifteenth Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production (April 2018), in a response to my recent editorial saying as much. Now we have the data to back the assertions up.  

  • Biogen Leads Fight Against Supply-Chain Criminals
    Biogen Leads Fight Against Supply-Chain Criminals

    Lee Spach, Director, Global Product & Supply Chain Security, Biogen, says there are about 35,000 online pharmacies in the world. Ninety-eight percent are fake. They transact billions of dollars annually and seriously endanger patients. The criminals can expect a large return on their investment, with relatively little risk. Spach and Biogen are trying to change that. You can help.

  • President Trump, Communist China, and Pharma Outsourcing
    President Trump, Communist China, and Pharma Outsourcing

    President Clinton once said to reject permanent normal trade relations with China would be a mistake of hugely historic proportions. But years later will history judge “free" trade with China "a blunder of truly historic proportions from which America will never recover”? Enter Donald Trump. Our drug industry, dependent on China, should join the public discourse.

More FromLouis Garguilo
Louis Garguilo

Louis Garguilo



Louis Garguilo is chief editor and conference chair for Outsourced Pharma, and a contributing editor to Life Science Leader magazine. He studied public relations and journalism at Syracuse University (and holds a Master’s in English), and has 30+ years of international experience in business communications and development positions. Louis spent a decade at a global pharmaceutical contract research, development and manufacturing organization; served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; was chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and business communications consultant, including for the Osaka Medical Center for Cancer and Cardiovascular Diseases.